Clinical Utility of Pourmedia ViGBS Agar Medium for Group B Streptococcus Screening

Mitsunori Kaneda; Kumiko Takesue; Keisuke Mori; Kiyoshi Kamiyama

Clinical Utility of Pourmedia ViGBS Agar Medium for Group B Streptococcus Screening

Rinsho Biseibutshu Jinsoku Shindan Kenkyukai Shi. 2020 Dec 25;30(1):1-6.

Authors

Mitsunori Kaneda¹, Kumiko Takesue², Keisuke Mori², Kiyoshi Kamiyama²

Affiliations

¹ Department of Clinical Laboratory, Medical Diagnostic Center of URAWA Medical Association: 6-4-18 Tokiwa, Urawa-ku, Saitama 338-0011, Japan. Department of Natural Sciences, Graduate School of Integrative Science and Engineering, Tokyo City University: 1-28-1 Tamatsutsumi, Setagaya-ku, Tokyo 158-8557, Japan.
² Department of Clinical Laboratory, Medical Diagnostic Center of URAWA Medical Association: 6-4-18 Tokiwa, Urawa-ku, Saitama 338-0011, Japan.

PMID: 33478231

Abstract

Group B Streptococcus (hereinafter GBS) is the main pathogen in neonatal sepsis and meningitis, accounting for approximately one quarter of the cases. 1) Prevention of infection is therefore crucial. The GBS carriage testing of pregnant women is necessary to prevent infections. In this study, we examined the clinical utility of Pourmedia ViGBS agar medium (Eiken Chemical Co., Ltd.) in GBS screening, using a total of 197 vaginal and urine samples. Of these samples, 32 (16.2%) tested GBS positive with Pourmedia ViGBS agar medium, and 29 (14.7%) tested GBS positive with Nissui separated plate sheep blood agar/Drigalski agar medium (Nissui Pharmaceutical Co., Ltd.). These results indicate the usefulness of Pourmedia ViGBS agar medium as a GBS screening selective agar medium.

MeSH terms

Agar*
Culture Media
Female
Humans
Pregnancy
Pregnancy Complications, Infectious* / diagnosis
Streptococcal Infections* / diagnosis
Streptococcus agalactiae / isolation & purification

Substances

Culture Media
Agar